Skip to main content
PMC home page
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2015 Jul 1;6:670. doi: 10.3389/fmicb.2015.00670

CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data

Jianming Tang 1,*, Xuelin Li 1, Matthew A Price 2,3, Eduard J Sanders 4,5, Omu Anzala 6, Etienne Karita 7, Anatoli Kamali 8, Shabir Lakhi 9, Susan Allen 9,10, Eric Hunter 11, Richard A Kaslow 12,†, Jill Gilmour 13
PMCID: PMC4486831  PMID: 26191056

Abstract

In individuals with human immunodeficiency virus type 1 (HIV-1) infection, CD4:CD8 lymphocyte ratio is often recognized as a quantitative outcome that reflects the critical role of both CD4+ and CD8+ T-cells in HIV-1 pathogenesis or disease progression. Our work aimed to first establish the dynamics and clinical relevance of CD4:CD8 ratio in a cohort of native Africans and then to examine its association with viral and host factors, including: (i) length of infection, (ii) demographics, (iii) HIV-1 viral load (VL), (iv) change in CD4+ T-lymphocyte count (CD4 slope), (v) HIV-1 subtype, and (vi) host genetics, especially human leukocyte antigen (HLA) variants. Data from 499 HIV-1 seroconverters with frequent (monthly to quarterly) follow-up revealed that CD4:CD8 ratio was stable in the first 3 years of infection, with a modest correlation with VL and CD4 slope. A relatively normal CD4:CD8 ratio (>1.0) in early infection was associated with a substantial delay in disease progression to severe immunodeficiency (<350 CD4 cells/μl), regardless of other correlates of HIV-1 pathogenesis (adjusted hazards ratio (HR) = 0.43, 95% confidence interval (CI) = 0.29-0.63, P < 0.0001). Low VL (<10,000 copies/ml) and HLA-A*74:01 were the main predictors of CD4:CD8 ratio >1.0, but HLA variants (e.g., HLA-B*57 and HLA-B*81) previously associated with VL and/or CD4 trajectories in eastern and southern Africans had no obvious impact on CD4:CD8 ratio. Collectively, these findings suggest that CD4:CD8 ratio is a robust measure of immunologic health with both clinical and epidemiological implications.

Keywords: Africa, CD4:CD8 ratio, HIV-1, subtype, HLA, statistical models, viral load

Introduction

Progressive and systemic deterioration of immunologic health is a major hallmark of human immunodeficiency virus type 1 (HIV-1) pathogenesis (Taylor et al., 1989; Miedema, 1992; Brenchley et al., 2006; Maartens et al., 2014). The status of immunologic health is routinely assessed by several quantitative traits that center on CD4+ T-cells (CD4), including absolute CD4 count (cells/μl), CD4 percentage, change in CD4 count over time (CD4 slope), and/or two thresholds of severe CD4 deficiency (typically <350 and <200 cells/μl). These CD4-based and often partially correlated outcomes have also been used for studying quantitative trait loci (QTLs) in viral and host genomes (Lazaryan et al., 2011; Apps et al., 2013; Bartha et al., 2013; Peterson et al., 2013), with clear evidence that determinants of CD4-related manifestations of HIV-1 infection have rather limited overlap with those of either virologic measures (Lazaryan et al., 2011; Amornkul et al., 2013; Antoni et al., 2013; Peterson et al., 2013; Prentice et al., 2013, 2014b) or those of HIV-1 acquisition (Tang et al., 2008; Gao et al., 2010; Song et al., 2011; Merino et al., 2012). As CD4 data are sparse in many resource-poor regions, current understanding of immunologic health in HIV-1-infected Africans is still limited. Recent observation of a low threshold CD4 count (as few as 457 cells/μl) in HIV-1 seronegative Africans (Karita et al., 2009) may pose further challenges for making guidelines and policies based solely on CD4 count thresholds.

Among other immunologic markers of HIV-1 pathogenesis, CD8 activation (Giorgi et al., 1999; Sousa et al., 2002), CD8 exhaustion (Eichbaum, 2011; Hinrichs et al., 2011), CD4:CD8 ratio (Taylor et al., 1989; Zaman et al., 2000; Margolick et al., 2006; Pahwa et al., 2008), and delayed-type hypersensitivity (DTH) to recall antigens (Dolan et al., 2007) can also serve as outcome measures that reflect immunologic health (or lack of). Documentation of CD4:CD8 ratio as a genetically controlled trait in healthy humans (Amadori et al., 1995; Ferreira et al., 2010) implies that factors associated with CD4:CD8 ratio may offer novel insights about the wide spectrum of HIV-1-related immune malfunction. The CD4:CD8 ratio is rarely measured below 1.0 in healthy subjects (Amadori et al., 1995), so an inverted CD4:CD8 ratio is often viewed as clinically relevant (Zaman et al., 2000; Pahwa et al., 2008). Examination of CD4:CD8 ratio as another quantitative trait can be important to patient care, especially when T-cell immunophenotyping using banked or newly collected samples becomes increasingly feasible (Sambor et al., 2014). Accordingly, our main objective was to characterize the relationships between CD4:CD8 ratio and HIV-1 disease outcomes in an African cohort with sufficient follow-up data.

Materials and Methods

Study Population

This study focused on native Africans who were recent HIV-1 seroconverters (SCs) enrolled from Kenya, Rwanda, Uganda, and Zambia under a uniform study protocol developed and implemented by the International AIDS Vaccine Initiative (IAVI; Price et al., 2011; Amornkul et al., 2013). All volunteers underwent written informed consent procedures prior to study-related procedures that were approved annually by institutional review boards at all collaborating institutions.

Follow-Up Strategies before and after HIV-1 Infection

Identification of SCs relied on frequent (monthly to quarterly) testing of HIV-1 seronegative subjects at high risk of acquiring HIV-1 infection through heterosexual and homosexual exposure, with the vast majority being partners of HIV-1 discordant, heterosexual couples and/or individuals diagnosed with sexually transmitted infections. As described in detail elsewhere (Karita et al., 2007; Amornkul et al., 2013; Prentice et al., 2013), the estimated date of HIV-1 infection (EDI) for each subject was defined as one of the following: (i) the midpoint between the last seronegative and first positive HIV-1 antibody tests, (ii) 2 weeks before the first positive test for HIV-1 p24 antigen in plasma, (iii) 10 days before the first positive test for plasma viral load (VL) while being negative for both p24 and rapid HIV-1 antibody tests, and (iv) event date for the only known high-risk exposure. Following confirmation of HIV-1 infection (detection of VL), clinical visits were scheduled monthly for the first 3 months after EDI, quarterly for the 3–24 months interval, and every 6 months thereafter. Initiation of antiretroviral therapy (ART) followed national guidelines (Ngongo et al., 2012), and all visits and VL measurements after ART initiation were excluded. In all, 499 SCs (Supplementary Table S1) were selected based on availability of biological specimens for DNA extraction and human leukocyte antigen (HLA) class I genotyping, as well as at least three time points of VL in the early chronic phase (3–24 months) of infection, with no gap greater than 1 year between two consecutive VL measurements. The SCs excluded from analyses (n = 81) were mostly those with limited follow-up (less than three eligible visits for various outcome measures) or lack of biological specimens.

Quantification of HIV-1 Viral Load (VL)

Plasma VL (HIV-1 RNA copies/ml) was measured at a central location (Clinical Laboratory Services, Johannesburg, South Africa) using the Amplicor Monitor v1.5 assay (Roche Applied Science, Indianapolis, IN, USA) through January 2011 and the Abbott real-time HIV-1 v1.0 assay (Abbott Laboratories, Abbott Park, IL, USA) thereafter and following good clinical laboratory practices (Amornkul et al., 2013). Eligible VLs in the 3- to 24-month interval were all beyond the acute-phase of infection (Tang et al., 2011). The geometric mean VL (Prentice et al., 2014b) was calculated from the average log10 VL during the 3- to 24-month interval and then divided into three categories (Fideli et al., 2001; Tang et al., 2010) with biological and epidemiological implications: low (<4.0 log10), medium (4.0–5.0 log10), and high (>5.0 log10). For log10-transformation, all VLs below the lower limit of detection (400 RNA copies/mL) were assumed to be 1.30 (half of log10 400), as other alternatives (e.g., 2.30 log10 or 200 copies/ml) yielded similar results in data analyses (Prentice et al., 2014b).

Viral Sequencing and Human Leukocyte Antigen (HLA) Class I Genotyping

Methods for HIV-1 pol gene sequencing and subtype determination have been described elsewhere (Tang et al., 2011; Amornkul et al., 2013; Prentice et al., 2014b). PCR-based assays also resolved allelic variants at three HLA class I genes (HLA-A, HLA-B, and HLA-C; Tang et al., 2010; Merino et al., 2012; Prentice et al., 2014b). Assignment of HLA haplotypes followed algorithms described elsewhere (Tang et al., 2010; Prentice et al., 2013, 2014b).

Immunologic Outcomes and Immunodeficiency in the Absence of Antiretroviral Therapy

For our study population, CD4 count was the initial outcome defined by T-cell immunophenotyping (Amornkul et al., 2013; Prentice et al., 2013) performed at individual clinics using the FACScount System (Beckman Coulter Ltd., London, UK). These assays also quantified CD4:CD8 ratio. For consistency with previously applied criteria, we considered CD4:CD8 ratio >1.0 as an indication of immunologic health (lack of disease progression). The date of the first of two consecutive visits with CD4 count <350 cells/μL was deemed the onset of severe immunodeficiency (Amornkul et al., 2013).

Descriptive Statistics

With a focus on data beyond the acute phase (first 3 months) of HIV-1 infection, subjects with contrasting CD4:CD8 ratios (>1.0 versus ≤1.0) during the 3- to 24-month period after EDI were compared for their overall baseline characteristics, including t-test for quantitative variables with a normal distribution, Wilcoxon’s rank-sum test for quantitative variables lacking a normal distribution, and χ2 or Fisher exact test for categorical variables (Supplementary Table S1). These and other analytical procedures were done using SAS, version 9.3 (SAS Institute, Cary, NC, USA). All baseline characteristics that differed between two major patient groups (CD4:CD8 ratio >1.0 versus ≤1.0) were treated as covariates in subsequent analyses. The inclusion of data over the 24- to 36-month period after EDI (not applicable to all subjects) led to similar conclusions.

Central Hypothesis and Analytical Procedures

This study aimed to test a central hypothesis that CD4:CD8 ratio as a composite outcome is distinct from two conventional measures (VL and CD4 slope) of HIV-1 pathogenesis, after accounting for potential confounders like geography (eastern and southern Africa), sex, and major viral subtypes (A1, C, and others). Statistical analyses focused on: (i) the dynamics of CD4:CD8 ratio, VL, and CD4 slope in the first 3 years after EDI; (ii) the pairwise relationships between CD4:CD8 ratio, VL, and CD4 slope; (iii) the prognostic value of early CD4:CD8 ratio for subsequent disease progression; and (iv) host and viral correlates of CD4:CD8 ratio. Main analytical procedures included the following: (a) local regression (LOESS) curves, (b) Spearman’s correlation test, (c) Kaplan–Meier curves and Cox proportional hazards models, and (d) logistic regression models. To maximize sample size, CD4:CD8 ratio from the 3- to 24-month interval was analyzed first. Alternative analyses considered the addition of data from the 24- to 36-month period (not applicable to all subjects). Summary statistics, including correlation coefficients (rho), regression beta (β), HR, odds ratio (OR), 95% CI, P-value, and false discovery rate (FDR or q-value) were tabulated using SAS, version 9.3, as described in earlier work related to the same cohort (Prentice et al., 2013, 2014b). The overall performance of multivariable logistic regression models was also assessed using the area under the curve (AUC) estimates (C-statistics).

Refinement of Host Genetic Factors Based on Linkage Disequilibrium (LD) and Biological Relevance

Wherever possible, HLA factors showing putative associations with CD4:CD8 ratio were refined by analyses of LD profiles and HLA haplotypes in subjects before and after stratification by geography (eastern versus southern Africa), with further reference to fully resolved haplotypes seen in other populations (Cao et al., 2001). Alternative analyses of 2- and 3-locus HLA haplotypes were deemed informative if the adjusted effect sizes improved over those for the component alleles. The likelihood of biological relevance was evaluated in the context of (i) HIV-1-specific CTL epitopes and escape mutations documented for individual HLA allelic products1,2 (Carlson et al., 2014), (ii) relationships to single nucleotide polymorphisms (SNPs) that have biological and/or epidemiological importance (Horton et al., 2004; Fellay et al., 2009; Prentice et al., 2014a), and (iii) other evidence as reported in the literature, especially the Finemapping Data Portal3 (Farh et al., 2015) and the HaploReg database4 (last accessed in April 2015).

Results

The Dynamics of CD4:CD8 Ratio in Primary HIV-1 Infection

Among native African subjects enrolled between February 2006 and December 2011, 196 Zambians, 125 Ugandans, 102 Kenyans, and 76 Rwandans had at least three measurements of CD4:CD8 ratio and other outcomes (VL and CD4 slope) within the 3- to 24-month intervals after EDI. Overall, CD4:CD8 ratio was steady during this early period of infection (Figure 1), with a heavy bias toward the ≤1.0 (abnormal) group (P = 2.2 × 10-16 in normality tests). For seven consecutive sliding time windows (3 months each), the pairwise Spearman rho values for comparing cross-sectional CD4:CD8 ratio ranged from 0.71 to 0.88 (P < 0.0001 for all; Table 1). The mean CD4:CD8 ratio within the 3- to 24-month intervals had a modest, inverse correlation with geometric mean VL (Spearman rho = -0.33, P < 0.0001), accompanied by a weak, positive correlation with CD4 slope (Spearman rho = 0.14, P < 0.01; Table 2). A negative correlation between geometric mean VL and CD4 slope was weak as well (rho = -0.20, P < 0.0001), suggesting that these three outcome measures were mostly independent of one another. Similar results were observed when additional data from the 24- to 36-month period were included in the correlation analyses (Figure 1 and Table 2).

FIGURE 1.

FIGURE 1

Open in a new tab

CD4:CD8 T-lymphocyte ratio in early human immunodeficiency virus type 1 (HIV-1) infection, in the absence of antiretroviral therapy. Results are shown for 499 seroconverters (SCs; native Africans) with 4,144 person-visits during the 3- to 36-month period after estimated date of infection. Thick and thin lines correspond to the mean ratio and 95% confidence interval (CI), respectively. Arrow points to the threshold of abnormal (inverted) ratio that is rarely seen in HIV-1 seronegative, healthy subjects.

Table 1.

Pairwise Spearman’s correlation coefficients (rho) for cross-sectional CD4:CD8 ratio measurements (seven consecutive time windows in early human immunodeficiency virus type 1 (HIV-1) infection).

Time window (subjects)a 3–6 6–9 9–12 12–15 15–18 18–21 21-24
(a) 3–6 months (424) 1.00
(b) 6–9 months (446) 0.81 1.00
(c) 9–12 months (458) 0.78 0.83 1.00
(d) 12–15 months (434) 0.78 0.82 0.88 1.00
(e) 15–18 months (425) 0.75 0.80 0.87 0.88 1.00
(f) 18–21 months (400) 0.71 0.76 0.83 0.84 0.86 1.00
(g) 21–24 months (375) 0.72 0.74 0.82 0.83 0.84 0.86 1.00
Open in a new tab

aThe timing for measuring CD4:CD8 ratio in 499 subjects is not always equally spaced, as precision in inferring dates of infection can vary by the three methods used (see Materials and Methods). P < 0.0001 in all tests. The maximum value under each time window is shown in bold.

Table 2.

Spearman correlation coefficients for mean CD4:CD8 ratio, set-point viral load (VL), and CD4 slope in 499 HIV-1 seroconverters (SCs).

3–24 months after EDIa
 3–36 months after EDIa
Outcomes CD4:CD8 ratio VL CD4 slope CD4:CD8 ratio VL CD4 slope
CD4:CD8 ratio (mean) 1.00 1.00
VL (geometric mean) -0.33 1.00 -0.33 1.00
CD4 slope 0.14 -0.20 1.00 0.20 -0.25 1.00
Open in a new tab

aResults are shown for two overlapping time intervals after estimated date of infection (EDI). The maximum value under each column is shown in bold.

The Prognostic Value of Early CD4:CD8 Ratio

Beyond the initial 3-month period (acute phase) after EDI, the first available CD4:CD8 ratio was relatively normal (>1.0) in 113 (or 22.6%) subjects and abnormal (≤1.0) in the remainder (77.4%). The rates of subsequent disease progression, as measured by time to CD4 count <350 cells/μL, clearly differed (log-rank P < 0.0001) between these two immunologic subgroups (Figure 2). A favorable prognosis (a crude HR of 0.37, 95% CI = 0.25–0.54, P < 0.0001) for patients with CD4:CD8 ratio >1.0 was evident over a time span of up to 7 years after EDI. These HR estimates were insensitive to statistical adjustments for other potential confounders, including demographics, two reported HLA variants (HLA-B*45:01 and B*81:01), and geometric mean VL: the adjusted HR for CD4:CD8 ratio >1.0 was 0.43 (95% CI = 0.29–0.63, P < 0.0001; Table 3).

FIGURE 2.

FIGURE 2

Open in a new tab

Progression to severe immunodeficiency among 499 HIV-1 SCs stratified by early CD4:CD8 ratio. Based on the first CD4:CD8 ratio measured beyond the initial 3-month period of infection, subjects are divided into two subgroups (CD4:CD8 ratio >1.0 in green color versus ≤1.0 in red color). The first of two consecutive visits with CD4+ T-cell count <350 cells/μL is plotted as the event time (Amornkul et al., 2013). The numbers of subjects available at nine time points are boxed and color coded. The crude hazard ratio (HR) and 95% CI are based on a Cox proportional hazards model (unadjusted). The adjusted model is shown in Table 3.

Table 3.

Progression to severe immunodeficiency (CD4 count <350 cells/μL): prognosis based on early CD4:CD8 ratio and other potential factors in 499 HIV-1 seroconverters.

Factors in model (no. of subjects) n HR 95% confidence interval (CI) P
Age > 40 years 75 1.78 1.29-2.45 <0.001
Age ≤ 40 years 424 1.00 – –
Female sex 187 1.16 0.88–1.52 0.294
Male sex 312 1.00 – –
Region: Zambia (southern Africa) 196 1.28 0.98–1.66 0.066
Region: eastern Africa 303 1.00 – –
HLA-B*45:01a 81 1.38 1.01–1.90 0.043
HLA-B*81:01a 25 0.44 0.22–1.00 0.049
Low VL (<10,000 RNA copies/mL) 142 0.33 0.22–0.49 <0.0001
Medium VL (10,000–100,000) 265 1.00 – –
High VL (>100,000) 92 1.67 1.23–2.25 <0.001
Early CD4:CD8 ratiob >1.0 113 0.43 0.29–0.63 <0.0001
Early CD4:CD8 ratiob ≤1.0 386 1.00 – –
Open in a new tab

aAs reported previously for the study cohort (based on interim data analyses; Amornkul et al., 2013; Prentice et al., 2013).

bFirst available measurement beyond the acute phase of infection (see text).

Factors Associated with CD4:CD8 Ratio

In stepwise univariable models (Supplementary Table S1), patients defined by their average CD4:CD8 ratios (>1.0 and ≤1.0) during the 3- to 24-month period after EDI were highly comparable (P > 0.13 in all tests) in terms of age, sex ratio, and distribution of five HLA variants (B*18, B*45, B*53, B*57, and B*81) that were previously associated with VL and/or CD4 count in the same cohort (Amornkul et al., 2013; Prentice et al., 2013). The two immunologic subgroups did show clear differences in geography (P < 0.001) and HIV-1 subtype (P = 0.009). Similar results were seen when the time horizon for calculating the average CD4:CD8 ratio was expanded to the 3- to 36-month period after EDI (data not shown). Further analyses focused on the average CD4:CD8 ratios over the 3- to 24-month period alone.

HLA-A*74:01 as a Novel Correlate of CD4:CD8 Ratio

Apart from hypothesis-testing for B*18, B*45, B*53, B*57, and B*81 (all with related evidence from earlier work), 29 other HLA class I variants were also frequent enough (≥5%) for association analyses. Based on regression models adjusted for age, sex, and geography, A*74:01 was most noteworthy for its favorable association with mean CD4:CD8 ratio >1.0 (OR = 2.29, P = 0.005, q = 0.172), while the remaining HLA class I variants were readily dismissed (P > 0.05 in all tests; Supplementary Table S2).

HLA-A*74:01-Related Haplotypes

In the study population, HLA-A*74:01 was in weak LD (r2 < 0.05) with B*35:01, B*42 (*42:01 and *42:02), B*44 (*44:03 and *44:15), B*49:01, B*58 (*58:01 and *58:02), C*02:10, C*04:01, and C*17:01 (P-values ranging from 0.0001 to 0.042). The individual haplotypes defined by LD profile and random combination were too rare (<1.8% for all) to justify sub-analyses. Data stratification by country did not facilitate further analysis of HLA haplotypes either.

Bioinformatic Analyses for HLA-A*74:01

The current HIV Molecular Immunology Database has compiled a total of 991 HIV-1 CTL epitope polymorphisms associated with HLA-A alleles, but none for HLA-A*74:01. Additional data specific for southern Africans (including Zambians; Carlson et al., 2014) indicate that HLA-A*74:01, as part of the A03 supertype, has been associated with three mutations in HIV-1 Gag (R20K/S, R91X, and V94I) and two in Pol (R432K and R521K). These mutations often overlap with the optimal epitope, GR11 in HIV-1 Gag-p24, for A*74:01 (Matthews et al., 2011). Meanwhile, an intergenic SNP (rs9468675 G/T, also known as rs114788707 or rs118104426) that effectively tags A*74:01 in an African population (Yoruban; de Bakker et al., 2006) has been mapped to an enhancer element (the HaploReg version 2 database), without any confirmed functional attributes.

Joint Assessment of Host and Viral Factors as Independent Correlates of CD4:CD8 Ratio

During the 3- to 24-month period after EDI, geography, HLA-A*74:01 and low VL (<10,000 RNA copies/mL) were the major correlates of CD4:CD8 ratio >1.0, with adjusted P-values between <0.0001 and 0.048 (Table 4). Two potential confounders (age and sex) observed in healthy subjects (Amadori et al., 1995) had no obvious impact on CD4:CD8 ratio >1.0 in this cohort (adjusted P > 0.43), whereas low VL (<10,000 copies/ml) and HLA-A*74:01 were independent predictors of healthy CD4:CD8 ratio (OR > 2.0 in all tests), with further confirmation by an alternative model in which geography was replaced by viral subtype as a covariate (Table 5). By excluding three subjects with missing data (viral sequencing failed), the alternative model revealed that HIV-1 subtype A1 and infrequent subtypes (not A1 and not C) were positively associated with CD4:CD8 ratio >1.0 (adjusted OR = 1.74 and 1.89, P = 0.042 and 0.045, respectively, when compared with subtype C). Further refinement for the infrequent HIV-1 subtypes was not feasible, as neither subtype D (n = 75) nor recombinant forms (n < 20) were common enough to allow separate models.

Table 4.

Host and viral factors as independent correlates of immunologic health (average CD4:CD8 ratio >1.0) in early HIV-1 infection.

Ratio >1.0 during the 3- to 24-month intervalsa
Factors in the modelb n ORb 95% CI Adjusted P
Age > 40 yearsc 75 1.14 0.61–2.15 0.678
Female sexc 187 1.21 0.75–1.93 0.436
Region (Zambia) 196 0.61 0.37–1.00 0.048
HLA-A*74:01 64 2.07 1.14–3.78 0.017
Low VL (<10,000 RNA copies/mL) 142 2.71 1.67–4.39 <0.0001
High VL (>100,000) 92 0.53 0.24–1.17 0.117
Open in a new tab

aOverall area under the curve (AUC) = 0.70 and P < 0.0001 for the model. Estimates of odds ratio (OR) and 95% CI have been adjusted for all factors in the model.

bReference groups for several multi-entry factors are listed in Table 3.

cAge and sex have been associated with CD4:CD8 ratio in healthy subjects (Amadori et al., 1995).

Table 5.

An alternative model for assessing correlates of immunologic health (mean CD4:CD8 ratio >1.0) in 496 HIV-1 SCs.

Mean CD4:CD8 ratio >1.0 in the 3–24 months period
Factors in the joint modelc Subjects ORd 95% CId Adjusted P
Age > 40 years 75 1.13 0.60–2.13 0.704
Female sex 185 1.15 0.72–1.84 0.569
HLA-A*74:01 63 2.01 1.09–3.68 0.025
HIV-1 subtype A1 183 1.74 1.02–2.95 0.042
HIV-1 subtype C 215 1.00 – –
Other HIV-1 subtypes (not A1 or C) 98 1.89 1.02–3.50 0.045
Low VL (<10,000) 140 2.62 1.61–4.26 <0.0001
High VL (>100,000) 91 0.52 0.23–1.15 0.106
Open in a new tab

aHIV-1 subtype replaces geography as a covariate; three subjects with missing information for viral subtype are excluded; one of them has HLA-A*74:01.

bOverall AUC = 0.70, P < 0.0001 for the model.

cReference groups for several multi-entry factors are listed in Table 3.

dEstimates of OR and 95% CI have been adjusted for all factors in the model.

AUC Estimates for Predicting Healthy CD4:CD8 Ratios

For the overall cohort of 499 SCs, host and viral factors had robust AUC estimates for predicting average CD4:CD8 ratios >1.0 during the 3- to 24-month period after EDI (AUC = 0.70, P < 0.0001; Table 4). In additional models that tested two major HIV-1 subtypes separately, host and viral factors had similar predictive value for subtype C (AUC = 0.70, P < 0.0001) and subtype A1 infection (AUC = 0.65, P < 0.001) (data not shown).

Discussion

In line with our primary hypothesis, prospective data from 499 HIV-1 SCs did suggest that CD4:CD8 ratio in early (primary) infection has three main features. First, this ratio is relatively stable during the first 3 years of HIV-1 infection, in that regard resembling the set-point VL (Prentice et al., 2014b). Second, early CD4:CD8 ratio is predictive of subsequent disease progression: a favorable ratio (>1.0) is a clear sign of immunologic health that is strongly associated with a delayed course to severe CD4 deficiency. Third, CD4:CD8 ratio has a rather weak correlation with two conventional and extensively studied outcome measures (VL and CD4 slope). As a result, QTLs (i.e., HLA factors) associated with CD4:CD8 ratio are expected to differ starkly from the well-known QTLs already documented for VL and CD4 count (Amornkul et al., 2013; Peterson et al., 2013; Prentice et al., 2013).

Although CD4 depletion is an important manifestation of HIV-1 pathogenesis, exacerbation of immunologic health can be further attributable to persistent immune activation (expression of CD38 and HLA-DR) driven by viral antigens and microbial translocation (Jirillo et al., 1991; Savarino et al., 2000; Brenchley et al., 2006; Douek, 2007). T-cell exhaustion (expression of PD-1) is another trait in HIV-1 infection that has gained close attention (Day et al., 2006; Petrovas et al., 2006; Trautmann et al., 2006). As immunophenotyping becomes increasingly feasible in resource-poor nations (Karita et al., 2009), analyses of banked and newly collected samples should help further elucidate the relationships between CD4:CD8 ratio and other established correlates of T-cell function. These parameters of immunologic health can be gradually incorporated into the HIV-1 treatment continuum when the focus shifts from virologic suppression to immune recovery and management of comorbidities (Buggert et al., 2014; Serrano-Villar et al., 2014). Until then, evidence from earlier work based on general populations (Amadori et al., 1995; Ferreira et al., 2010) and our analyses of HLA class I genes in HIV-1-infected Africans can pave the way for studying CD4:CD8 ratio as a genetically modulated and clinically relevant trait.

A putative association between HLA-A*74:01 and a favorable CD4:CD8 ratio is rather consistent with previous reports based on analyses of HIV-1 acquisition, VL and/or CD4 count after HIV-1 infection (Koehler et al., 2010; Leslie et al., 2010; Tang et al., 2010; Lazaryan et al., 2011; Peterson et al., 2013). Genetic diversity in our cohort of native Africans enabled us to rule out the potential confounding by other HLA class I alleles, which is a critical step toward a definitive dissection of functional mechanisms. The description of three HIV-1-specific CTL epitopes in another African cohort (Matthews et al., 2011) already suggests that antigen presentation by HLA-A*74:01 can direct CTL responses to multiple antigens. Furthermore, unlike HLA-B and HLA-C alleles that also mediate innate immunity through interaction with natural killer (NK) cell receptors (Carrington et al., 2008), HLA-A*74:01 is unlikely to have a prominent role in innate immunity. Such distinction, if proved true, would effectively eliminate the need for considering A*74:01-driven NK cell function that is expected to be more generic than adaptive immune responses.

HLA-A*74:01 and its proxy (allele T of rs9468675) are mostly restricted to Africans (de Bakker et al., 2006). While further attention to A*74:01-restricted HIV-1 epitopes (Matthews et al., 2011) may ultimately uncover relevant mechanisms of immunologic health in subjects with HLA-A*74:01, other loci (beyond the HLA-A locus) are known to regulate CD8 T-lymphocyte function in populations of European ancestry (Cruz et al., 2006, 2008; Ferreira et al., 2010). Further examination of SNPs associated with CD4:CD8 ratio in healthy subjects can be helpful (Ferreira et al., 2010), especially since A*74:01-positive subjects (~15%) in this study (Supplementary Table S2) can only account for <50% of those with a favorable CD4:CD8 ratio (Figure 2).

In our previous studies that focused on VL and CD4 count (two conventional outcome measures) in HIV-1-infected Africans, HLA-A*74:01 was not recognized as a prominent factor in systematic evaluation of cross-sectional and longitudinal data (Amornkul et al., 2013; Prentice et al., 2013). Instead, HLA-B*18, B*45, B*53, B*57, and B*81 were implicated, often in a time-sensitive manner (Amornkul et al., 2013; Prentice et al., 2013). To further establish independent correlates of CD4:CD8 ratio, multivariable models conditioned on VL and CD4 slope did not obscure the association of HLA-A*74:01 with immunologic health, suggesting that individuals with HLA-A*74:01 might have certain unique immunologic traits that analyses of VL and CD4 count alone cannot reveal. In other words, HLA factors may operate in different immune pathways to impact the manifestations of HIV-1 infection.

Host genetics aside, correlates of CD4:CD8 ratio further included HIV-1 subtype, even when VL was retained as a covariate in the analytic model (Table 5). High-throughput deep sequencing may eventually facilitate a better understanding of viral characteristics (Haaland et al., 2013) that are important to immunologic health, as viruses from acute and early chronic phases of infection can be readily compared for replicative fitness (Claiborne et al., 2015; Yue et al., 2015).

Despite our emphasis on longitudinal data, our study did have two apparent limitations that are worth reiterating. First, CD4:CD8 ratio was rarely measured before acquisition of HIV-1 infection. For subjects with CD4:CD8 ratio ≤1.0 soon after HIV-1 infection, we were unable to determine if this was the result of rapid disease progression or low CD4:CD8 ratio before infection. Second, the opportunity for studying opportunistic infections and other AIDS-defining conditions was precluded by treatment guidelines. These limitations can be a recurring issue in follow-up studies as well. A revisit to earlier cohorts with prolonged follow-up without therapy may offer a feasible option for answering questions about AIDS-related outcomes.

Overall, our study represents the first comprehensive comparison of CD4:CD8 ratio with VL, CD4 trajectory and CD4 deficiency in an African cohort with frequent follow-up. It is evident that measurement of CD4:CD8 ratio can have added value for predicting subsequent disease progression, at least irrespective of other known factors (demographics, HIV-1 subtypes, etc.). Certain characteristics seen in subjects with a favorable CD4:CD8 ratio, including HLA variants, may offer valuable insights into the determinants or mechanisms of immunologic health in HIV-1 infection. Recent approaches to fine mapping of causal variants in HLA genes and neighboring loci have provided promising leads for follow-up studies (McLaren et al., 2012; Prentice et al., 2014a; Farh et al., 2015).

Author Contributions

JT, MP, ES, OA, EK, AK, SL, SA, EH, RK, and JG designed the study. ES, OA, EK, AK, SL, and SA assembled the cohort and gathered clinical data. JT and RK supervised and reviewed genotyping. XL and JT managed and analyzed the data. All authors contributed to the writing and proof reading of this manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was funded in part by IAVI and made possible by the generous support from many donors, including: the Bill & Melinda Gates Foundation, the Ministry of Foreign Affairs of Denmark, Irish Aid, the Ministry of Finance of Japan, the Ministry of Foreign Affairs of the Netherlands, the Norwegian Agency for Development Cooperation, the United Kingdom Department for International Development, and the United States Agency for International Development (USAID). The full list of IAVI donors is available at www.iavi.org. Additional funding for this work came from (i) the United States National Institute of Allergy and Infectious Diseases (NIAID), through two R01 grants (AI071906 to RK/JT and AI064060 to EH), (ii) the Fogarty AIDS International Training and Research Program (AITRP; grant FIC 2D43 TW001042 to SL), and (iii) the KEMRI-Wellcome Trust Research Programme at the Centre for Geographical Medicine Research-Kilifi (Wellcome Trust award #077092). Submission of this study for publication required approval by the director of Kenya Medical Research Institute (KEMRI) and by KEMRI and IAVI representatives, but the contents are the responsibility of the individual authors and do not necessarily reflect the views of IAVI, NIAID, USAID, or the United States government. We are grateful to Pat Fast for critical reading of earlier versions of this manuscript; Ilene Brill, Paul Farmer, Dongning He, Travis R. Porter, Heather A. Prentice, and Wei Song for assistance with genotyping and data management; Heather A. Prentice and Xiang-Yang Lou for verifying SAS programs and summary statistics.

Footnotes

Supplementary Material

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmicb.2015.00670

Click here for additional data file. (61.2KB, DOCX)

References

  1. Amadori A., Zamarchi R., De Silvestro G., Forza G., Cavatton G., Danieli G. A., et al. (1995). Genetic control of the CD4/CD8 T-cell ratio in humans. Nat. Med. 1 1279–1283. 10.1038/nm1295-1279 [DOI] [PubMed] [Google Scholar]
  2. Amornkul P. N., Karita E., Kamali A., Rida W. N., Sanders E. J., Lakhi S., et al. (2013). Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa. AIDS 27 2775–2786. 10.1097/QAD.0000000000000012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Antoni G., Guergnon J., Meaudre C., Samri A., Boufassa F., Goujard C., et al. (2013). MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection. AIDS 27 1707–1716. 10.1097/QAD.0b013e328360a4bd [DOI] [PubMed] [Google Scholar]
  4. Apps R., Qi Y., Carlson J. M., Chen H., Gao X., Thomas R., et al. (2013). Influence of HLA-C expression level on HIV control. Science 340 87–91. 10.1126/science.1232685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bartha I., Carlson J. M., Brumme C. J., Mclaren P. J., Brumme Z. L., John M., et al. (2013). A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife 2:e01123 10.7554/eLife.01123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brenchley J. M., Price D. A., Douek D. C. (2006). HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7 235–239. 10.1038/ni1316 [DOI] [PubMed] [Google Scholar]
  7. Buggert M., Frederiksen J., Noyan K., Svard J., Barqasho B., Sonnerborg A., et al. (2014). Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection. J. Immunol. 192 2099–2108. 10.4049/jimmunol.1302596 [DOI] [PubMed] [Google Scholar]
  8. Cao K., Hollenbach J., Shi X., Shi W., Chopek M., Fernandez-Vina M. A. (2001). Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62 1009–1030. 10.1016/S0198-8859(01)00298-1 [DOI] [PubMed] [Google Scholar]
  9. Carlson J. M., Schaefer M., Monaco D. C., Batorsky R., Claiborne D. T., Prince J., et al. (2014). Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345 1254031 10.1126/science.1254031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carrington M., Martin M. P., Van Bergen J. (2008). KIR-HLA intercourse in HIV disease. Trends Microbiol. 16 620–627. 10.1016/j.tim.2008.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Claiborne D. T., Prince J. L., Scully E., Macharia G., Micci L., Lawson B., et al. (2015). Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc. Natl. Acad. Sci. U.S.A. 112 E1480–E1489. 10.1073/pnas.1421607112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cruz E., Vieira J., Almeida S., Lacerda R., Gartner A., Cardoso C. S., et al. (2006). A study of 82 extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload. BMC Med. Genet. 7:16 10.1186/1471-2350-7-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cruz E., Whittington C., Krikler S. H., Mascarenhas C., Lacerda R., Vieira J., et al. (2008). A new 500 kb haplotype associated with high CD8+ T-lymphocyte numbers predicts a less severe expression of hereditary hemochromatosis. BMC Med. Genet. 9:97 10.1186/1471-2350-9-97 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Day C. L., Kaufmann D. E., Kiepiela P., Brown J. A., Moodley E. S., Reddy S., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 350–354. 10.1038/nature05115 [DOI] [PubMed] [Google Scholar]
  15. de Bakker P. I., Mcvean G., Sabeti P. C., Miretti M. M., Green T., Marchini J., et al. (2006). A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 38 1166–1172. 10.1038/ng1885 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dolan M. J., Kulkarni H., Camargo J. F., He W., Smith A., Anaya J. M., et al. (2007). CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat. Immunol. 8 1324–1336. 10.1038/ni1521 [DOI] [PubMed] [Google Scholar]
  17. Douek D. (2007). HIV disease progression: immune activation, microbes, and a leaky gut. Top. HIV Med. 15 114–117. [PubMed] [Google Scholar]
  18. Eichbaum Q. (2011). PD-1 signaling in HIV and chronic viral infection–potential for therapeutic intervention? Curr. Med. Chem. 18 3971–3980. 10.2174/092986711796957239 [DOI] [PubMed] [Google Scholar]
  19. Farh K. K., Marson A., Zhu J., Kleinewietfeld M., Housley W. J., Beik S., et al. (2015). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518 337–343. 10.1038/nature13835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Fellay J., Ge D., Shianna K. V., Colombo S., Ledergerber B., Cirulli E. T., et al. (2009). Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 5:e1000791 10.1371/journal.pgen.1000791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ferreira M. A., Mangino M., Brumme C. J., Zhao Z. Z., Medland S. E., Wright M. J., et al. (2010). Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am. J. Hum. Genet. 86 88–92. 10.1016/j.ajhg.2009.12.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fideli U. S., Allen S. A., Musonda R., Trask S., Hahn B. H., Weiss H., et al. (2001). Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res. Hum. Retroviruses 17 901–910. 10.1089/088922201750290023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gao X., O’brien T. R., Welzel T. M., Marti D., Qi Y., Goedert J. J., et al. (2010). HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS 24 1835–1840. 10.1097/QAD.0b013e32833c3219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Giorgi J. V., Hultin L. E., Mckeating J. A., Johnson T. D., Owens B., Jacobson L. P., et al. (1999). Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179 859–870. 10.1086/314660 [DOI] [PubMed] [Google Scholar]
  25. Haaland R. E., Johnson J. A., Tang J. (2013). Recent advances in research of HIV infection: implications of viral and host genetics on treatment and prevention. Public Health Genomics 16 31–36. 10.1159/000345935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hinrichs C. S., Borman Z. A., Gattinoni L., Yu Z., Burns W. R., Huang J., et al. (2011). Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117 808–814. 10.1182/blood-2010-05-286286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Horton R., Wilming L., Rand V., Lovering R. C., Bruford E. A., Khodiyar V. K., et al. (2004). Gene map of the extended human MHC. Nat. Rev. Genet. 5 889–899. 10.1038/nrg1489 [DOI] [PubMed] [Google Scholar]
  28. Jirillo E., Covelli V., Brandonisio O., Munno I., De Simone C., Mastroianni C. M., et al. (1991). HIV-infection and in vivo lipopolysaccharide-induced release of cytokines. An amplified mechanism of damage to the host. Acta Neurol. (Napoli) 13 188–196. [PubMed] [Google Scholar]
  29. Karita E., Ketter N., Price M. A., Kayitenkore K., Kaleebu P., Nanvubya A., et al. (2009). CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS ONE 4:e4401 10.1371/journal.pone.0004401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Karita E., Price M., Hunter E., Chomba E., Allen S., Fei L., et al. (2007). Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 21 403–408. 10.1097/QAD.0b013e32801481b7 [DOI] [PubMed] [Google Scholar]
  31. Koehler R. N., Walsh A. M., Saathoff E., Tovanabutra S., Arroyo M. A., Currier J. R., et al. (2010). Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania. J. Infect. Dis. 202 1562–1566. 10.1086/656913 [DOI] [PubMed] [Google Scholar]
  32. Lazaryan A., Song W., Lobashevsky E., Tang J., Shrestha S., Zhang K., et al. (2011). The influence of human leukocyte antigen class I alleles and their population frequencies on human immunodeficiency virus type 1 control among African Americans. Hum. Immunol. 72 312–318. 10.1016/j.humimm.2011.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Leslie A., Matthews P. C., Listgarten J., Carlson J. M., Kadie C., Ndung’u T., et al. (2010). Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J. Virol. 84 9879–9888. 10.1128/JVI.00320-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Maartens G., Celum C., Lewin S. R. (2014). HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384 258–271. 10.1016/S0140-6736(14)60164-1 [DOI] [PubMed] [Google Scholar]
  35. Margolick J. B., Gange S. J., Detels R., O’gorman M. R., Rinaldo C. R., Jr., Lai S. (2006). Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 42 620–626. 10.1097/01.qai.0000223028.55080.9d [DOI] [PubMed] [Google Scholar]
  36. Matthews P. C., Adland E., Listgarten J., Leslie A., Mkhwanazi N., Carlson J. M., et al. (2011). HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703. J. Immunol. 186 5675–5686. 10.4049/jimmunol.1003711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. McLaren P. J., Ripke S., Pelak K., Weintrob A. C., Patsopoulos N. A., Jia X., et al. (2012). Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum. Mol. Genet. 21 4334–4347. 10.1093/hmg/dds226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Merino A. M., Song W., He D., Mulenga J., Allen S., Hunter E., et al. (2012). HLA-B signal peptide polymorphism influences the rate of HIV-1 acquisition but not viral load. J. Infect. Dis. 205 1797–1805. 10.1093/infdis/jis275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Miedema F. (1992). Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic. Rev. 3 173–193. [PubMed] [Google Scholar]
  40. Ngongo P. B., Priddy F., Park H., Becker J., Bender B., Fast P., et al. (2012). Developing standards of care for HIV prevention research in developing countries – a case study of 10 research centers in Eastern and Southern Africa. AIDS Care 24 1277–1289. 10.1080/09540121.2012.656572 [DOI] [PubMed] [Google Scholar]
  41. Pahwa S., Read J. S., Yin W., Matthews Y., Shearer W., Diaz C., et al. (2008). CD4+/CD8+ T cell ratio for diagnosis of HIV-1 infection in infants: women and infants transmission study. Pediatrics 122 331–339. 10.1542/peds.2007-2308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Peterson T. A., Kimani J., Wachihi C., Bielawny T., Mendoza L., Thavaneswaran S., et al. (2013). HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort. Tissue Antigens 81 93–107. 10.1111/tan.12051 [DOI] [PubMed] [Google Scholar]
  43. Petrovas C., Casazza J. P., Brenchley J. M., Price D. A., Gostick E., Adams W. C., et al. (2006). PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203 2281–2292. 10.1084/jem.20061496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Prentice H. A., Pajewski N. M., He D., Zhang K., Brown E. E., Kilembe W., et al. (2014a). Host genetics and immune control of HIV-1 infection: fine mapping for the extended human MHC region in an African cohort. Genes Immun. 15 275–281. 10.1038/gene.2014.16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Prentice H. A., Price M. A., Porter T. R., Cormier E., Mugavero M. J., Kamali A., et al. (2014b). Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates. Virology 449 254–262. 10.1016/j.virol.2013.11.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Prentice H. A., Porter T. R., Price M. A., Cormier E., He D., Farmer P. K., et al. (2013). HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? J. Virol. 87 4043–4051. 10.1128/JVI.03302-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Price M. A., Wallis C. L., Lakhi S., Karita E., Kamali A., Anzala O., et al. (2011). Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res. Hum. Retroviruses 27 5–12. 10.1089/aid.2010.0030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sambor A., Garcia A., Berrong M., Pickeral J., Brown S., Rountree W., et al. (2014). Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. J. Immunol. Methods 409 107–116. 10.1016/j.jim.2014.04.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Savarino A., Bottarel F., Malavasi F., Dianzani U. (2000). Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 14 1079–1089. 10.1097/00002030-200006160-00004 [DOI] [PubMed] [Google Scholar]
  50. Serrano-Villar S., Sainz T., Lee S. A., Hunt P. W., Sinclair E., Shacklett B. L., et al. (2014). HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 10:e1004078 10.1371/journal.ppat.1004078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Song W., He D., Brill I., Malhotra R., Mulenga J., Allen S., et al. (2011). Disparate associations of HLA class I markers with HIV-1 acquisition and control of viremia in an African population. PLoS ONE 6:e23469 10.1371/journal.pone.0023469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sousa A. E., Carneiro J., Meier-Schellersheim M., Grossman Z., Victorino R. M. (2002). CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169 3400–3406. 10.4049/jimmunol.169.6.3400 [DOI] [PubMed] [Google Scholar]
  53. Tang J., Cormier E., Gilmour J., Price M. A., Prentice H. A., Song W., et al. (2011). Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J. Virol. 85 8894–8902. 10.1128/JVI.00439-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Tang J., Malhotra R., Song W., Brill I., Hu L., Farmer P. K., et al. (2010). Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships. PLoS ONE 5:e9629 10.1371/journal.pone.0009629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Tang J., Shao W., Yoo Y. J., Brill I., Mulenga J., Allen S., et al. (2008). Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples. J. Immunol. 181 2626–2635. 10.4049/jimmunol.181.4.2626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Taylor J. M., Fahey J. L., Detels R., Giorgi J. V. (1989). CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J. Acquir. Immune Defic. Syndr. 2 114–124. [PubMed] [Google Scholar]
  57. Trautmann L., Janbazian L., Chomont N., Said E. A., Wang G., Gimmig S., et al. (2006). Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat. Med. 12 1198–1202. 10.1038/nm1482 [DOI] [PubMed] [Google Scholar]
  58. Yue L., Pfafferott K. J., Baalwa J., Conrod K., Dong C. C., Chui C., et al. (2015). Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog. 11:e1004565 10.1371/journal.ppat.1004565 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Zaman M. M., Recco R. A., Raguthu L., Likki S., Reddy S. (2000). Characteristics of HIV-1-infected patients with CD4:CD8 lymphocyte ratio normalization on antiretroviral therapy. AIDS Patient Care STDS 14 647–649. 10.1089/10872910050206568 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (61.2KB, DOCX)

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES